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Abstract
The potential application of multiplexed quantum dot labeling (MQDL) for cancer detection and prognosis and monitoring
therapeutic responses has attracted the interests of bioengineers, pathologists and cancer biologists. Many published
studies claim that MQDL is effective for cancer biomarker detection and useful in cancer diagnosis and prognosis, these
studies have not been standardized against quantitative biochemical and molecular determinations. In the present study,
we used a molecularly characterized human prostate cancer cell model exhibiting activated c-Met signaling with epithelial
to mesenchymal transition (EMT) and lethal metastatic progression to bone and soft tissues as the gold standard, and
compared the c-Met cell signaling network in this model, in clinical human prostate cancer tissue specimens and in a
castration-resistant human prostate cancer xenograft model. We observed c-Met signaling network activation, manifested
by increased phosphorylated c-Met in all three. The downstream survival signaling network was mediated by NF-kB and
Mcl-1 and EMT was driven by receptor activator of NF-kB ligand (RANKL), at the single cell level in clinical prostate cancer
specimens and the xenograft model. Results were confirmed by real-time RT-PCR and western blots in a human prostate
cancer cell model. MQDL is a powerful tool for assessing biomarker expression and it offers molecular insights into cancer
progression at both the cell and tissue level with high degree of sensitivity.
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Introduction
Semi-conductor quantum dots (QDs) fluorescent nanoparticles
have been recognized as one of the great recent advances for our
ability to detect relevant biomarkers expressed by cells, tissues and
sera [1,2,3,4,5]. The unique optical and electronic properties of
QDs include their narrow and symmetrical emission bands, size-
and material-tunable light emission, high surface to volume ratio,
photostability, signal brightness and sensitivity, and simultaneous
excitation of multiple fluorescence colors making it possible to
detect multiple targets simultaneously at the single cell level [3,6].
Quantum dot labeling, QDL, is superior to conventional organic
dyes for cell and tissue staining, especially since the latter yield
broad bandwidth with overlapping signal emissions and are highly
susceptible to photobleaching. Multiplexing biomarkers with
different colors provides significant advantages over traditional
organic or fluorescent dyes for the detection and analysis of
dynamic changes in proteins and nucleic acids in cells or tissues
under pathophysiologic conditions. QDL has been applied
successfully to detect the levels of expression of genes in situ
associated with important biologic processes such as epithelial to
mesenchymal transition [6] in cancer metastasis [7], protein
biomarkers in the blood, the presence of nucleic acids, microRNA
and DNA methylation in sera or tissue extracts with samples
barcoded for rapid processing by automated protocols [8,9,10]. In
the present study, we employed multiplexed quantum dot labeling
(MQDL) to detect the activated c-Met-mediated cell signaling
pathway leading to EMT, cancer growth and bone and soft tissue
metastasis in a novel prostate cancer metastasis model [11,12,13].
We confirmed the levels of gene expression assessed by MQDL
with gene expression as determined by RT-PCR and western
blots. We then applied the MQDL protocol to determine if the c-
Met cell signaling pathway and EMT are activated in a castration-
resistant prostate cancer (CRPC) animal model and in clinical
prostate cancer specimens obtained from patients with high
Gleason scores and bone metastasis. We observed that activation
of c-Met is closely linked to EMT in cancer cells and their
subsequent increased migration, invasion and metastasis
[14,15,16]. c-Met signal activation in human prostate cancer has
important clinical implications: 1) c-Met downstream signaling
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survival in several human solid tumor models including prostate
cancer [15,17,18,19]. 2) Since targeting c-Met and VEGFR2
downstream signaling with a synthetic multiple tyrosine kinase
inhibitor, cabozantinib (XL-184), resulted in remarkable resolu-
tion of bone and soft tissue metastases in a large number of
patients with solid tumors including CRPC patients [20,21], it
would be important to show if these cell signaling pathways might
be activated in clinical specimens and in relevant tumor xenograft
models. We used a human prostate cancer cell line to demonstrate
that c-Met activation confers EMT and prostate cancer bone and
soft tissue metastases and investigated in depth the c-Met signaling
activation by molecular analyses with results confirmed by
MQDL. We then employed MQDL to evaluate c-Met signaling
activation in clinical prostate cancer tissue specimens and
correlated the results with a castration-resistant human prostate
cancer xenograft model. We showed that MQDL, coupled with
Vectra Image Analysis, enhances the quantitative profiling
capability of individual biomarkers at the single cell level. A series
of biomarkers associated with EMT, such as decreased expression
of EpCAM, and increased expression of N-cadherin, vimentin and
RANKL, and c-Met signal activation, including VEGF, neuropilin
1, p-c-Met and phospho(p)-NF-kB p65 [15,22], were analyzed.
The results of these studies showed a remarkable parallelism of
EMT and c-Met activation between the prostate cancer cell
model, the CRPC xenograft model and clinical prostate cancer
specimens. The methodologies established in the present study
could be of significant value in the near future to characterize
other activated signaling pathways in clinical specimens, interro-
gate molecular mechanisms underlying cancer progression,
identify druggable targets, and follow up the clinical response of
patients to therapeutic intervention.
Materials and Methods
Cell culture and cell transfection
The LNCaP cell line, kindly provided by late Dr. Gary Miller of
the University of Colorado (Denver, CO), was cultured in RPMI
1640 medium (Invitrogen) supplemented with 5% fetal bovine
serum (Atlanta Biologicals, Lowrenceville, GA), penicillin
(100 mg/ml) and tetracycline (100 u/ml) at 37uC in humidified
atmosphere with 5% CO2. The establishment of clones overex-
pressing RANKL protein was reported previously [23]. Briefly, a
full-length cDNA encoding human RANKL from OriGene
(Rockville, MD) was cloned unidirectionally to p36FLAG- myc-
CMV-25 (Sigma-Aldrich, St. Louis, MO) at the NotI and XbaI
restriction enzyme sites. Following transfection of LNCaP cells at
75% confluency with flag-tagged RANKL and neo plasmid using
Lipofectamine 2000 (Invitrogen) in a 6-well plate for 48 h, cells
were trypsinized and seeded onto a 15 cm dish. The stable
LNCaP-neo and LNCaP-RANKL cells were subjected to G418
selection (400 mg/ml) and single cell clones were isolated and
maintained in 200 mg/ml G418 for RNA and protein extraction
and immunoassay using 8-well chambered slides (Thermo
Scientific, Rochester, NY). Three LNCaP-RANKL and 2
LNCaP-neo cell clones were selected. Since their biochemical
phenotypes were similar we used one clone of each for the study.
Reverse transcriptase (RT) PCR
Total RNA from cells was isolated using RNeasy Mini Kit
(Qiagen Sciences, Inc.; Germantown, MD) according to the
manufacturer’s instructions. Complementary DNA (cDNA) was
generated from 3 mg of total RNA using SuperScriptH III First-
Strand Synthesis System (Invitrogen; 1 ml of cDNA was subjected
to PCR analyses using the following primers : RANKL F, 59-TGG
ATC ACA GCA CAT CAG AGC AG-39; RANKL R, 59-TGG
GGC TCA ATC TAT ATC TCG AAC-39; E-cadherin F, 59-
GCC AAG CAG CAG TAC ATT CTA CAC G-39; E-cadherin
R, 59-GCT GTT CTT CAC GTG CTC AAA ATC C-39;N -
cadherin F, 59-GAT GTT GAG GTA CAG AAT CGT; N-
cadherin R, 59-GGT CGG TCT GGA TGG CGA-39; vimentin
F, 59-GGA CTC GGT GGA CTT CTC; vimentin R, 59-CGC
ATC TCC TCC TCG TAG-39, c-Met F, TGGGAATCTGC-
CTGCGAA; c-Met R, CCAGAGGACGACGCCAAA. The PCR
reaction cycles involved an initial denaturation at 94uC for
10 min, 36 cycles of 94uC, 1 min, 55 uC, 30 sec; for RANK-
L72uC, 1 min followed by a final 72uC for 10 min extension. For
E-cadherin and N-cadherin gene amplification, the PCR reactions
ran for 32 cycles and the annealing temperatures were 55uC and
47uC, respectively for 30 sec. For vimentin and GAPDH
amplification, the PCR reactions ran for 28 cycles with annealing
temperatures at 48uC for 30 sec. The amplified PCR products
were detected and analyzed on 1% agarose gel.
Western blot analysis
Cells were lysed in RIPA buffer containing 16 protease
inhibitor cocktail (Thermo Fisher Scientific; Rockford, IL) and
centrifuged, and the supernatants were collected and quantified
using the Bradford Protein Assay (Thermo Fisher Scientific). The
cell lysates (20–30 mg) were resolved on a 4–12% Bis-Tris gradient
SDS-PAGE (Invitrogen; Carlsbad, CA) under reducing conditions,
followed by transblotting onto nitrocellulose membrane (BioRad
Laboratories; Hercules, CA), and blocked in 5% non-fat milk/
PBST for one hour at room temperature (RT) and incubated with
diluted primary Abs in blocking buffer at 4uC overnight. The
source and dilution of primary Abs were: RANKL (sc-
74261;1:400), E-cadherin (sc-7870; 1:1000), vimentin (sc-6260;
1:500), c-Met (sc-10; 1:500) (Santa Cruz Biotechnology; Santa
Cruz, CA), N-cadherin (#610920; 1:200) (BD Transduction
Laboratories; San Jose, CA and Santa Cruz Biotechnology), p-
Met (Tyr-1230/34/35) (#44888G; 1:500) (Invitrogen), p-NF-kB
p65 (Ser536) (#3033; 1:1000), NF-kB p65 (#4764;1:1000) (Cell
Signaling Technology; Danvers, MA). Production and usage of
androgen receptor antibody (PG21;1:500) were previously report-
ed [24]. The membranes were rinsed 36 with PBST, incubated
with peroxidase-conjugated anti-mouse or anti-rabbit secondary
Abs at RT for one hour and rinsed 36 with PBST. The signals
were visualized using ECL Plus reagent (GE Healthcare
Biosciences; Pittsburg, PA). Restore Plus Western Blot Stripping
Buffer (Thermo Fisher Scientific) was used prior to re-probing with
different Abs.
In vivo experiments
All animal procedures were performed according to an
approved protocol from the Institutional Animal Care and Use
Committee (IACUC#2999, Cedars-Sinai Medical Center, and
A10-0100, University of British Columbia). LNCaP-RANKL and
LNCaP-neo cells (1610
6 cells/50 ml PBS) were inoculated
intracardially into 5- to 7-week-old male athymic nude mice
(Charles River; n=20 for LNCaP-RANKL and n=15 for
LNCaP-neo). All mice were regularly monitored for metastatic
tumor formation which first occurred at 8 wks. Animals were
sacrificed at 12 wks.
Prostate cancer tissue specimens
Formalin-fixed and paraffin-embedded (FFPE) human prostate
cancer specimens were obtained from Department of Pathology of
the Cedars-Sinai Medical Center (IRB# Pro 00021228). Addi-
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Dr. Fouad Habib at the University of Edinburgh, Scotland, and
Dr. Hua Yang at the Jilin University, China. Usage of clinical
specimens was approved by the human tissue institutional review
committees at the respective institutions.
CRPC xenografts
To establish working protocols for single and sequential multiple
QD labeling, we chose to use a LTL-313 CRPC xenograft model
since it mimics castration-resistant prostate cancer and provides
consistent and readily available multiple tissue specimens critical
for the development and establishment of a new MQDL protocol.
FFPE tissues from a castration resistant prostate cancer (CRPC)
LTL-313 (Living Tumor Laboratory, www.livingtumorcentre.
com) xenograft model were obtained from Vancouver Cancer
Center, BC Cancer Agency, Vancouver, Canada. The LTL-313
tumor line was developed from prostate needle biopsy specimen
from an 80-year old patient diagnosed with Gleason Score 8
prostate cancer with a serum PSA level of 17 ng/ml at the time of
diagnosis [25]. The tumor line development protocol was
approved by the Clinical Research Ethics Board of the University
of British Columbia, in accordance with the Laboratory Animal
Guidelines of the Institute of Experimental Animal Sciences
(Human specimen use was with approvals from University of
British Columbia, Canada (IRB# UBC BCCA REB #H04-
60131). Briefly, to establish castration-resistant prostate cancer,
fresh LTL-313 tumor tissues from the 5th generation of grafting
were cut into 36361 mm pieces and re-grafted into the subrenal
capsules of male NOD-SCID mice. The animals were maintained
for tumor formation for two months before castration to remove
androgens. Three weeks after castration, when the tumor volume
was significantly reduced, the remaining tumor tissues were
harvested and prepared as FFPE tissue blocks. Xenongraft tissues
used in this study were derived from 9 tumors from castrated mice
and 5 tumors from 5 intact mouse hosts supplemented with
testosterone that had undergone sham operation.
Immunoassay reagents
The primary antibodies (Abs) and their sources were: mouse
monoclonal Abs to human EpCAM (VU-1D9) and RANKL
(12A668) from Novus Biologicals (St. Charles, MO); mouse
Table 1. RANKL overexpressing LNCaP cells induced high
incidences of bone and soft tissue metastases.
Lymph
nodes Bones*
Adrenal
glands Lung
LNCaP-neo 0/15 0/15 0/15 0/15
LNCaP-RANKL 18/20 (90%) 20/20 (100%) 17/20 (85%) 8/20 (40%)
LNCaP-RANKL and LNCaP-neo cells (1610
6 cells/50 ml PBS) were inoculated
intracardially into 5- to 7-week-old male athymic nude mice (LNCaP-RANKL
n=20; LNCaP-neo n=15). Metastatic lesions were observed between 2–3
months after injection.
*Micro-CT tomography detected bone lesions in limbs, ribs, jaw, and skull
determined by X-ray radiography and confirmed by histopathologic staining
(H&E).
doi:10.1371/journal.pone.0028670.t001
Figure 1. RANKL overexpression induced epithelial to mesencymal transition. RANKL-transfected LNCaP cells induced EMT in
histomorphology (A) and gene expression in mRNA (B) and protein (C). Data represent one of 3 RANKL-stably transfected and 2 neo-stably
transfected LNCaP cell clones.
doi:10.1371/journal.pone.0028670.g001
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cadherin (24E10) from Cell Signaling Technology; rabbit polyclonal
Ab to androgen receptor, AR, (PG 21), provided by Dr. Gail Prins
from University of Illinois (Urbana, IL); goat polyclonal Ab to
neuropilin-1 (C-19), rabbit polyclonal Abs to N-cadherin (H-63),
Mcl-1 (S-19), p-NF-kB p65 (Ser 536), and VEGF (A-20) from Santa
Cruz Biotechnology, Inc.; and rabbit polyclonal Ab to p-c-Met
(pYpYpY1230/1234/1235) from Invitrogen. Secondary Abs used in
the study were prepared in a cocktail of biotinylated Abs to mouse,
rabbit, and goat IgG (Vector Laboratories, Inc., Burlingame, CA).
Phosphate-buffered saline (PBS) and streptavidin-conjugated QDs at
565-, 585-, 605-, 625-, 655- and 705 nm wavelengths as 1 mMs t o c k
solution were purchased from Invitrogen.
Immunohistochemical (IHC) staining
IHC followed our published protocol [26] with minor
modifications. FFPE sections (4 mm) were deparaffinized, rehy-
drated, and subjected to antigen retrieval. After incubating in Dual
Endogenous Enzyme Block solution (DEEB, Dako, Carpinteria,
CA) for 10 minutes, the section was treated with primary antibody
diluted with Antibody Diluent solution (Dako) as follows:
RANKL(1:100), c-Met(1:50), neuropilin 1 (1:100), androgen
receptor (1:200), N-Cadherin (1:100), Mcl-1 (1:100); p-NF-kB
p65 (Ser536) (1:100), VEGF (1:50) and p-c-Met [pYpYpY1230/
1234/1235] (1:100), vimentin (1:100), and E-cadherin (1:200) at
4uC overnight. The section was then washed 3 times in PBST
(PBS containing 0.2% Tween 20) for 5 minutes per washing. To
Figure 2. RANKL overexpression activated c-Met signaling components detected by single quantum dot labeling, SQDL. Differential
QD labeling of proteins was performed in LNCaP-neo (A) and LNCaP-RANKL (B) cells using DAPI nuclear staining as reference. For each analysis, QD
labeled protein expression is presented in pseudocolor, with the overlaid image of DAPI and QD signals (Merged). 6400.
doi:10.1371/journal.pone.0028670.g002
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EnVision
+ Dual Link System-HRP (Dako), which contained horse
radish peroxidase conjugated goat antibodies to mouse and rabbit
Ig. The section was washed 3 times for 5 minutes each, and
specific stains were developed with 3,39-diaminobenzidine (Dako).
Single QD Labeling (SQDL)
The IHC staining protocol was modified for single QD
labeling. Streptavidin-conjugated QDs (565-, 585-, 605-, 625-,
655- and 705 nm) were prepared as 10 nM in PBS with 6% IgG-
free, protease-free BSA (Jackson Immunoresearch; West Grove,
PA). Antigen retrieved tissues or fixed cell samples were
incubated in PBS containing 2.5% horse serum (Vector
Laboratories) and 20% Streptavidin Block Reagent (Invitrogen)
for 20 minutes, followed by treatment with primary Abs as
described above in the above immunoreagents section in PBS
plus 1% horse serum and 20% Biotin Block Reagent (Invitrogen)
at 4uC overnight. After a 365 min PBST (PBS+ 0.4% Triton X-
100) rinse specimens were incubated with the secondary Ab
cocktail at room temperature for 30 min and then incubated with
the respective streptavidin-QD at 37uC for 60 min. At the end of
each incubation, the specimens were subjected to routine
365 min PBST (PBS+ 0.4% Triton X-100) rinse. After the final
rinse, the slides were mounted in aqueous mounting media
containing 496-diamidino-2-phenylindole (DAPI) (Vector Labo-
ratories) for imaging. The Ab dilutions were described in the IHC
section above.
Multiplexed QD Labeling (MQDL)
The single QD labeling protocol was modified for MQDL, in
which a single tissue section was subjected to staining for
multiple markers in a sequential manner. For each biomarker
test, labeling started with a streptavidin blocking, followed by
primary Ab reaction and biotinylated secondary Ab incubation,
and reaction with streptavidin-conjugated QD at a specified
wavelength. Sections were incubated sequentially (with a
365 min PBST rinse after each incubation). Primary Abs and
dilutions in MQDL were identical to those used for SQDL. The
immunoreaction sequences were: 1) Anti-Neuropilin-1 Ab,
2 hours, room temperature; biotinylated horse anti-goat IgG,
at room temperature, 30 min; streptavidin-QD705, at 37uC,
1 hour. 2) Anti- p-c-Met Ab, at 4uC, overnight; biotinylated
horse anti-rabbit IgG, at room temperature, 30 min; streptavi-
din-QD655 at 37uC, 1 hour. 3) Anti-VEGF Ab, at room
temperature, 2 hours; biotinylated horse anti-rabbit IgG, at
roomtemperature, 30 min; streptavidin-QD625 at 37uC, 1 hour.
4) Anti- p-p65-NFkBA ba t4 uC, overnight; biotinylated horse
anti-rabbit IgG at room temperature, 30 min; streptavidin-
QD565 at 37uC, 1 hour. 5) Anti- RANKL Ab at room
temperature, 2 hours; biotinylated horse anti-mouse IgG at
room temperature, 30 min; streptavidin-QD585 at 37uC,
1 hour. 6) Mounting in aqueous mounting media containing
DAPI. Ab concentrations were described in the IHC section.
Sections of FFPE LNCaP-RANKL human prostate cancer cells
were used as a positive control. For negative control, primary
Abs were replaced with isotype- and species-matched control
Abs and applied to an immediately adjacent tissue section, and
MQDL was performed in parallel with the tissue slide labeled
with the testing primary Abs.
Image Acquisition
A CRi spectral imaging system (Caliper Life Sciences,
Hopkinton, MA) with built-in Nuance v3.1 software was used to
document multispectral images following the manufacturer’s
recommended protocol. For each field of cancer tissue, serial
images were acquired at a 10 nm wavelength interval from 450 to
800 nm, a range chosen corresponding to the active fluorescent
QDs. It generates an unprocessed image ‘‘cube’’ as a stack of 36
separate images with each image containing the complete spectral
information for every pixel at that given wavelength. All images
were acquired at 4006 magnification, with a 50 milliseconds
exposure. To avoid variations in labeling due to cell heterogeneity,
five images from different cancerous tissue sites were taken for
each tissue specimen for subsequent quantification.
Figure 3. Quantification of differential gene expression subsequent to RANKL overexpression in LNCaP cells. Cell-based average
intensity counts from 1,000 each of neo- and RANKL-transfected LNCaP clones were quantified using inForm software. Statistically significant changes
in protein expression were observed (P,0.05).
doi:10.1371/journal.pone.0028670.g003
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Image deconvolution or unmixing protocol was used to extract
specific labeling by a specified QD. A spectral library for 565, 585,
605, 625, 655, and 705 nm was built for deconvolution by
performimg multiple SQDLs using androgen receptor (AR)
antibody without final DAPI counterstaining on serially adjacent
tissue sections. The positive labeling of AR was confirmed by
parallel IHC staining on adjacent tissues. The spectrum of DAPI
was obtained by mounting the adjacent tissue in the aqueous
mounting medium containing DAPI. Spectra of tissue autofluo-
rescence were acquired for each tissue from a negative control
slide (see MQDL section) prepared by IHC without fluorescent
markers. Autofluorescence reduction was performed using Real
Component Analysis plug-in software. The spectral library was
then used to unmix the cube. The separate spectral contributions
to the data ‘cube’ are outputted as designated colored intensity
maps. These images represent the distribution of each of the QDs
and autofluorescence in the tissue. After the deconvolution of the
images, the background labeling was filtered and only the true
positive signals were shown on the images of the Figures presented.
Signal Quantification
The spectral library was used to deconvolute the imaging cube
to extract labeling of individual QD using inForm v1.3 software
(Caliper) following the recommended strategy. First, a training set
comprising two classes of tissue was created: ‘cancer’ and ‘non-
cancer’. The software was trained on these areas using the spectra
of both the DAPI counterstain and the multiplexed QD
immunolabeling and tested on 50 randomly selected cells from
each image to determine the accuracy of differentiating the two
classes. This process was repeated until further iterations no longer
improved the accuracy. Histological H/E images were then used
to localize cancer cells based on nuclear DAPI labeling. A built-in
algorithm was then used to define the cytoplasmic vs. nuclear
subcellular regions. Based on an analysis of images at 4006
magnification, the optimal threshold settings approximated: fixed
scale 200, minimum blob size 20, maximum blob size 10,000,
circularity threshold 0, edge sharpness 0, fill hole enabled (nuclear
parameters); inner distance to nucleus 1, outer distance to nucleus
7, minimum cytoplasm sample size 1, minimum signal range 0,
maximum signal range 65535 (cytoplasmic parameters). To
eliminate non-specific signals at the specified spectrum, an
acellular area within the field being analyzed was used as
background labeling. QD fluorescence intensity in each cell was
exported to an Excel spreadsheet (Microsoft, Seattle, WA) and
subjected to statistical analysis [27,28].
Results
Development of a quantitative QD labeling protocol for
the assessment of gene expression associated with the
activation of c-Met signaling and EMT in cultured human
LNCaP cells stably tansfected with RANKL
LNCaP bone and soft tissue metastases model: A novel LNCaP
bone metastasis model was developed by stable transfection of this
cell line with RANKL (LNCaP-RANKL), which drives EMT in
the transfected cells. When RANKL overexpressing LNCaP cells
were injected intracardially in mice they exhibited an increased
incidence of bone and soft tissue metastases (Table 1).
Validation of activated c-Met signaling components that lead to
EMT by RT-PCR, Western blot and Single Quantum Dot
Labeling, SQDL: Comparison of gene expression between stable
LNCaP-neo control and LNCaP-RANKL cells using RT-PCR
and Western blot showed evidence of activated c-Met signaling
through increased expression of c-Met, p-c-Met, and p-NFkB p65
(Figure 1). The cells underwent morphologic (Panel A) and
biochemical (Panels B and C) epithelial to mesenchymal transition,
with decreased intercellular adhesion mediated by E-cadherin and
EpCAM, and increased N-cadherin, vimentin and RANKL.
These assessments of c-Met signaling activation and EMT were
subjected to SQDL analyses with a specific effort to confirm if c-
Met activation and EMT occurred in this cell model of prostate
cancer progression. SQDL confirmed that in comparison to
control LNCaP-neo cells (Figure 2A), LNCaP-RANKL cells
(Figure 2B) had activated c-Met signaling as revealed by an
elevated expression of RANKL, c-Met, p-c-Met and p-NFkB p65
and evidence of EMT, a cadherin switch of elevated expression of
N-cadherin, vimentin and RANKL but decreased expression of E-
cadherin and AR. Quantitative analyses (Figure 3) of 1,000
randomly selected cancer cells by inForm software (Caliper)
supported the imaging data in which both AR and E-cadherin
expression was drastically decreased and activated c-Met signaling
components led to EMT, such as elevated expression of c-Met, p-
c-Met, p-NFkB p65, N-cadherin, vimentin, and RANKL were
observed in LNCaP-RANKL, when compared to LNCaP-neo
cells. This quantitative SQDL protocol was adopted for gene
expression analyses of an established CRPC LTL-313 xenograft
model.
Validation of c-Met signaling activation and EMT in the
CRPC LTL-313 model with results confirmed by IHC and
SQDL
To understand the clinical significance of c-Met signaling
activation and EMT in the LNCaP-RANKL model and the
associated increases in prostate cancer metastases, we defined the
c-Met signaling pathway and EMT in a CRPC LTL-313
xenograft model obtained from the Living Tumor Laboratory
(livingtumorcentre.com). We included additional c-Met signaling
associated genes such as neuropilin-1, VEGF, p-Akt, VEGFR2,
Mcl-1 and AR, which were characterized as mediators of c-Met
downstream survival signaling [15,21,29,30]. Figure 4 shows that
increased c-Met signaling-associated genes and decreased AR
expression in CRPC LTL-313 xenografts maintained in castrated
male hosts, as assessed by IHC (Panel A) and SQDL (Panel B)
compared to the xenografts maintained in intact mice with
androgen supplementation.
MQDL analysis demonstrated activated c-Met and EMT in a
CRPC LTL-313 xenograft model and primary and metastatic
human prostate cancer tissue specimens. A series of human
prostate cancer xenografts obtained from the Living Tumor
Laboratory was used to test the quantitative MQDL protocol. We
selected the LTL-313 model for this task because this model
exhibits CRPC characteristics with a propensity for primarily
lymph node, lung and liver metastases with infrequent bone
metastasis, when the tumors are implanted and grown under the
Figure 4. Castration induced c-Met activated and EMT associated proteins. The c-Met activated and EMT associated proteins were detected
in the CRPC LTL-313 xenograft model by conventional IHC (A) and SQDL (B). Castration increased a panel of genes in LTL-313 xenograft prostate
cancer and decreased AR expression compared to xenografts obtained from intact hosts by both IHC and SQDL. 6400.
doi:10.1371/journal.pone.0028670.g004
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castrated mice would develop castration resistance and have
activated c-Met signaling leading to EMT, when compared to
tumors grown in mice supplemented with exogenous androgen
(Figure 5A). Three approaches were taken: 1) to establish a robust
MQDL protocol to detect and quantify a panel of gene expressions
on the CRPC LTL-313 model tissue specimen with results
compared with SQDL; 2) to use this established quantitative
MQDL protocol to confirm if activation of c-Met and EMT occur
in the CRPC LTL-313 tissues maintained in the castrated hosts;
and 3) to demonstrate by the standardized MQDL protocol the
activation of c-Met and EMT induction in both primary and
skeletal metastatic human prostate cancer tissues. Figure 5B shows
the quantitative MQDL analyses of neuropili-1, p-c-Met, VEGF,
p-NFkB p65, and RANKL, previously reported to be associated
with c-Met signal activation [15,22] and EMT [26,31] in human
prostate cancer cells and in the CRPC LTL-313 model. We
showed activated c-Met signaling and EMT, as exhibited by
increased expression of neuropilin-1, VEGF, and RANKL protein
and activation of p-c-Met and p-NFkB p65 in the CRPC LTL-313
tumor model with higher expression and activation of these genes
in LTL-313 tumor xenografts maintained in castrated compared
to intact mice. As an internal control for minimizing the possible
fluorescence interference of multiple QD probes, we performed
MQDL side by side with the SQDL protocol (see above). The
elevated expression of the 5 studied genes was found to be
statistically significant by inFom quantitative analyses (Figure 5B).
We determined this panel of 5 genes in primary prostate cancer
specimens with different Gleason scores and found that expression
of neuropilin-1, VEGF, p-c-Met, RANKL, and p-NFkB p65 were
more elevated in poorly differentiated (Gleason score 10) than
moderately differentiated (Gleason score 7, 3+4) prostate cancer
(Figure 6). These results, taken together, confirmed that QD
labeling is highly sensitive and versatile and can be used for
multiplexing gene expression profiles in experimental models at
the single cell level.
Furthermore, we showed that some clusters of LTL-313 tumor
cells grown as xenografts in castrated male hosts underwent EMT
(marked as M in Figure 7A, Composite panel) and others only
partially transitioned to express both E and M markers (marked as
E/M in Figure 7A, Composite panel). Decreased expression of
EpCAM, an epithelial biomarker, with concomitant increased
expression of mesenchymal markers, such as N-cadherin and
RANKL, was observed (Figure 7A, Deconvoluted panels). These
data support the conclusion that castration promotes EMT in
prostate cancer cells in situ. Similar EMT was detected by MQDL
in clinical primary prostate cancers (Figure 7B). A cluster of
prostate cancer cells underwent EMT (M) while the other clusters
of cells underwent partial EMT (E/M) (Figure 7B, Composite
panel). Furthermore, Figure 8 demonstrates the co-expression of
epithelial EpCAM and mesenchymal RANKL, and vimentin
biomarkers in a metastatic bone tissue specimen.
Figure 5. Multiplexed quantum dot labeling (MQDL) simulta-
neously detected c-Met activated and EMT genes in a CRPC
LTL-313 xenograft model. Single tumor tissue sections from intact
and castrated hosts were subjected to sequential MQDL. Enhanced
expression of c-Met activated genes was detected in tumor tissues from
castrated hosts. (A) A stack of multiple images (Cube), nuclear staining
(DAPI), and individual gene expression (in pseudocolors) are shown.
Gene expression signals were superimposed with DAPI nuclear signals
to yield a composite image for analysis.6400. (B) Significant differences
in gene expression were found by quantification analysis of 1,000 cells
in each tumor specimen using inForm software (P,0.05).
doi:10.1371/journal.pone.0028670.g005
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Understanding the underlying molecular signaling pathway in
CRPC and prostate cancer bone and soft tissue metastases could
benefit patient care through improved disease surveillance and
selection of patients for more effective targeting. Considering the
limited amount of tissues and cells available from biopsies and
needle aspirates, and the challenges of tumor cell heterogeneity,
MQDL offers a valuable multiplexing capability to analyze
changes in cell signaling network components, at the single cell
level during prostate cancer progression in both preclinical models
and clinical specimens. The advantages of quantitative MQDL
over conventional IHC are: 1) Data obtained by quantitative
MQDL could contain spatial and temporal information on the
tissue specimens at the single cell level that can be easily integrated
into the already-known histomorphometric and immnohistochem-
ical information obtained from the tumor tissues or cells. 2) The
cell signaling network defined in tissue specimens could have
predictive value for assessing the progression and therapeutic
responsiveness of the prostate cancer. 3) Quantitative MQDL is
highly efficient for tissue and cell utilization and can be further
developed to monitor simultaneously multiple cell signaling
networks in human cancer cells in situ. The results of our studies
using quantitative MQDL suggest that activation of c-Met
signaling is responsible for driving prostate cancer cells to undergo
EMT, with prostate cancer cells acquiring increased capability for
cell migration, invasion and metastasis. The quantitative aspect of
the MQDL protocol is supported by a preclinical animal model in
which LNCaP-RANKL cells, shown to overexpress RANKL, had
activated c-Met signaling (Table 1, Figures 1,2,3), and underwent
EMT by acquiring increased ability to metastasize to mouse
skeleton and soft tissues, compared to parental LNCaP-neo cells.
In parallel, we presented evidence of activated c-Met and EMT in
a preclinical CRPC LTL-313 tumor xenograft model (Figures 4, 5,
and 7A). Using the established and validated MQDL protocol, we
consistently observed activated c-Met with evidence of EMT in
poorly differentiated (high Gleason score) and bone metastatic
clinical prostate cancer specimens (Figures 6 and 8) [15,26,32].
Taken together, we suggest that activation of c-Met signaling and
subsequent induction of EMT is probably a common feature of
prostate cancer cells, xenograft models and clinical prostate cancer
specimens exhibiting an increased propensity for lethal progres-
sion. These results suggest the possible link between c-Met-
mediated signaling activation, EMT and prostate cancer aggres-
Figure 6. MQDL assesses differential gene expression in clinical primary prostate cancer specimens. C-Met-activated and EMT protein
expressions in 5,000 cells of each representative prostate cancer tissues of Gleason scores 7 (3+4) and 10 (5+5) were compared. Expression intensities
were quantified with the inForm software and statistically compared (P,0.05).
doi:10.1371/journal.pone.0028670.g006
Figure 7. MQDL detects EMT biomarkers in CRPC LTL-313
prostate tumors harvested from castrated hosts and from
clinical prostate cancer. (A) The CRPC LTL-313 model showed
androgen deprivation induced more abundant expression of EMT
markers in a cluster of cells within the tumor region, as revealed by QD
labeling of EpCAM, N-Cad, and RANKL. (B) Similar EMT biomarkers were
detected in a clinical primary prostate cancer specimen (Gleason score
6; 3+3) with documented bone metastasis. M denotes cells that
completed EMT and E/M indicates cells undergoing partial EMT. 6400.
doi:10.1371/journal.pone.0028670.g007
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Met signaling network in prostate cancer cells could be considered
as one of the reasons why targeting c-Met and VEGFR2 kinases
with a small molecule, cabozantinib (XL-184), resolved bone and
soft tissue metastases in a broad spectrum of solid tumors in
patients [20,21]. Because of the small sample size used for the
determination of c-Met signal activation in clinical prostate cancer
specimens, a large scale of evaluation using clinical prostate cancer
specimens with known status of c-Met activation (e.g. sensitive vs.
resistant to cabozantinib) is warranted.
Several technical issues with MQDL deserve special attention.
1) Conjugation non-covalently of streptavidin-coated QD to
biotinylated secondary whole Ab is preferred to the direct
conjugation of QD to secondary Ab fragments via reduced
sulfhydryl-amine coupling. The former non-covalent method of
QD detection through the biotin-avidin complex in our practice
provides high labeling specificity and intensity. 2) Florescence
interference and florescence resonance energy transfer can present
a challenge for designing a suitable protocol to assess gene
expression in cells. Sweeney [5] provided earlier evidence that
order of the addition of antibodies and QDs could affect cell
labeling read-outs. We suggest conducting a series of combina-
tional tests to determine the optimal reaction sequence and using
matched primary Abs and QDs, a parallel set of negative control
Ab IgGs, and when possible confirming the MQDL results with
SQDL, IHC and Western blots. 3) The quality of the tissues and
cells and non-specific labeling should be carefully determined in
the immediately adjacent tissue sections to the actual sections used
for data acquisition and analyses. 4) For internal controls, b-actin
and EF1-a, two routinely used internal protein loading controls for
western blotting, were assessed in our current protocol. We found
that b-actin and EF1-a expression levels fluctuated depending on
the QD-conjugates used and the levels were different between
prostate tissues obtained from intact and castrated hosts in
preclinical models. These results are in agreement with the report
of Yurube T et al. [33] using b-actin as a control gene for
immunofluorescence detection of gene expression in a rat tail disc
degeneration model and found that b-actin was significantly
down-regulated rather than staying unchanged. Before establish-
ing a well-accepted internal control for MQDL, we used stringent
negative subtype matched antibodies as controls.
In summary, MQDL is demonstrated to be a highly dynamic
technique for assessing multiple gene expression at the single cell
level in formalin-fixed cell and tissue specimens. This protocol
could be of great value for assessing cell signaling network in
tissues and cells obtained from the clinic or from the laboratory.
Because of the unique photo-physical properties of QDs, MQDL
could provide a sensitive method to determine levels of gene
expression relevant to cell signaling networks or special biomarker
expression even when clinical materials are limited.
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